Oncolytics Biotech ONCY Stock
Oncolytics Biotech Price Chart
Oncolytics Biotech ONCY Financial and Trading Overview
| Oncolytics Biotech stock price | 0.4 USD |
| Previous Close | 1.93 USD |
| Open | 1.89 USD |
| Bid | 1.93 USD x 1200 |
| Ask | 2.04 USD x 800 |
| Day's Range | 1.87 - 2.06 USD |
| 52 Week Range | 0.87 - 2.28 USD |
| Volume | 716.34K USD |
| Avg. Volume | 286.36K USD |
| Market Cap | 124.98M USD |
| Beta (5Y Monthly) | 1.647907 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.28 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.4 USD |
ONCY Valuation Measures
| Enterprise Value | 94.6M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.7352943 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.850746 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.47 |
Trading Information
Oncolytics Biotech Stock Price History
| Beta (5Y Monthly) | 1.647907 |
| 52-Week Change | 98.97% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.28 USD |
| 52 Week Low | 0.87 USD |
| 50-Day Moving Average | 1.53 USD |
| 200-Day Moving Average | 1.51 USD |
ONCY Share Statistics
| Avg. Volume (3 month) | 286.36K USD |
| Avg. Daily Volume (10-Days) | 655.11K USD |
| Shares Outstanding | 64.09M |
| Float | 63.24M |
| Short Ratio | 0.95 |
| % Held by Insiders | 1.34% |
| % Held by Institutions | 1.47% |
| Shares Short | 325.6K |
| Short % of Float | 0.50% |
| Short % of Shares Outstanding | 0.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 10:95 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.85% |
| Return on Equity (ttm) | -80.61% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -27258000 USD |
| Net Income Avi to Common (ttm) | -24493000 USD |
| Diluted EPS (ttm) | -0.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.67M USD |
| Total Cash Per Share (mrq) | 0.46 USD |
| Total Debt (mrq) | 567K USD |
| Total Debt/Equity (mrq) | 2.2 USD |
| Current Ratio (mrq) | 13.876 |
| Book Value Per Share (mrq) | 0.402 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -24932000 USD |
| Levered Free Cash Flow (ttm) | -15044658 USD |
Profile of Oncolytics Biotech
| Country | United States |
| State | AB |
| City | Calgary |
| Address | 322 11th Avenue SW |
| ZIP | T2R 0C5 |
| Phone | 403 670 7377 |
| Website | https://www.oncolyticsbiotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Q&A For Oncolytics Biotech Stock
What is a current ONCY stock price?
Oncolytics Biotech ONCY stock price today per share is 0.4 USD.
How to purchase Oncolytics Biotech stock?
You can buy ONCY shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oncolytics Biotech?
The stock symbol or ticker of Oncolytics Biotech is ONCY.
Which industry does the Oncolytics Biotech company belong to?
The Oncolytics Biotech industry is Biotechnology.
How many shares does Oncolytics Biotech have in circulation?
The max supply of Oncolytics Biotech shares is 93.51M.
What is Oncolytics Biotech Price to Earnings Ratio (PE Ratio)?
Oncolytics Biotech PE Ratio is now.
What was Oncolytics Biotech earnings per share over the trailing 12 months (TTM)?
Oncolytics Biotech EPS is -0.28 USD over the trailing 12 months.
Which sector does the Oncolytics Biotech company belong to?
The Oncolytics Biotech sector is Healthcare.
Oncolytics Biotech ONCY included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19199.16 USD — |
+2.47
|
8.02B USD — | 18961.69 USD — | 19210.95 USD — | — - | 8.02B USD — |
| NASDAQ Composite Total Return XCMP | 23521.22 USD — |
+2.47
|
— — | 23230.28 USD — | 23535.65 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.46 USD — |
+1.8
|
— — | 113.76 USD — | 115.05 USD — | — - | — — |
| Nasdaq Health Care IXHC | 946.2 USD — |
+1.52
|
— — | 941.18 USD — | 951.02 USD — | — - | — — |
- {{ link.label }} {{link}}